替诺福韦酯与恩替卡韦治疗慢性乙型病毒性肝炎的效果及不良反应分析

Effects of tenofovir dipivoxil and entecavir on the treatment of chronic viral hepatitis B and adverse reactions

目的分析替诺福韦酯与恩替卡韦治疗慢性乙型病毒性肝炎(CHB)的效果及不良反应。方法回顾性研究2016年10月~2019年10月收治的600例CHB患者,随机分组,参照组(300例)给予恩替卡韦治疗,试验组(300例)给予替诺福韦酯治疗,对比两组肝功能指标、HBeAg转阴率、HBV-DNA转阴率、病毒学应答率、ALT复常率、不良反应发生率。结果两组治疗48周后ALT、TBil、AST指标均优于治疗前(P<0.05),但两组间比较无显著差异(P>0.05)。试验组HBeAg转阴率、HBV-DNA转阴率、病毒学应答率、ALT复常率、不良反应发生率与参照组比较无显著差异(P>0.05)。结论替诺福韦酯与恩替卡韦均可有效改善CHB患者肝功能指标,提高HBeAg转阴率,且不良反应发生率均较低,安全性较高。

Objective To analyze the effect of tenofovir dipivoxil and entecavir in the treatment of chronic viral hepatitis B(CHB)and the adverse reactions.Methods A prospective study of 600 patients with CHB treated in our hospital from October 2016 to October 2019 was randomly divided into two groups:the reference group(300 cases)was treated with entecavir and the test group(300 cases)was treated with tenofovir disoproxil.The liver function index,HBeAg negative rate,HBV-DNA negative rate,virological response rate,ALT normalization rate,and incidence of adverse reactions in the group.Results After 48 weeks of treatment in the test group,the ALT,TBil,and AST indexes were compared with the reference group,no significant difference between the two groups(P>0.05).Test group HBeAg negative rate,HBV-DNA negative rate,virological response rate,ALT normalization rate,incidence of adverse reactions were compared with the reference group,no significant difference between the two groups(P>0.05).Conclusion Both tenofovir dipivoxil and entecavir can effectively improve the liver function index of CHB patients and increase the negative conversion rate of HBeAg,and the incidence of adverse reactions is low,and the safety is high.